Zai Lab Ltd.
http://www.zailaboratory.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zai Lab Ltd.
Bristol Gets Tumor-Agnostic Second Approval For Augtyro
Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.
China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights
China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.
As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.
Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Zai Lab Limited
- Zai Lab (Shanghai) Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice